Start here if you're new
what it is
LifeVantage sells supplements, skincare, and energy products through a direct-selling model to consumers and distributors.
how it gets paid
Last year Lifevantage made $229M in revenue.
why it's growing
Revenue grew 14.2% last year (FY). 76.7% gross margin in the latest quarter on this feed matters because it signals strong unit economics—not weak pricing or bloated COGS in that print.
what just happened
A quarter near ~$57M (≈¼ of ~$229M FY) is the coherent scale—$96M and 97% vs. prior year do not reconcile to that annual total without a different line or period.
At a glance
B balance sheet — gets the job done, barely
35/100 earnings predictability — expect surprises
8.4x trailing p/e — the market's not buying it — or you found a deal
3.5% dividend yield — cash in your pocket every quarter
22.1% return on capital — every dollar works hard here
xvary composite: 40/100 — below average
What they do
LifeVantage sells supplements, skincare, and energy products through a direct-selling model to consumers and distributors.
This business turns product sales into a lot of leftover cash. Gross margin was 76.7% in the latest quarter, which means after product costs, most of each dollar is still there to pay everyone else. With just 232 employees and a 22.1% return on capital, you are looking at a small company that squeezes a lot of profit out of a small footprint.
How they make money
$229M
annual revenue · their business grew +14.2% last year
total revenue
$229M
+14.2%
The products that matter
core supplement franchise
Petandim®
portfolio anchor · exact sales not disclosed here
It sits inside a business that produced $229M in revenue last year, and it still appears to carry too much of the narrative weight. When one franchise does most of the storytelling, diversification starts to look cosmetic.
core
energy and focus supplement line
AXIO®
no standalone revenue disclosed
This is presented as a growth product, but this snapshot does not give you segment sales. That matters. In a $229M company, undisclosed product mix makes the growth case harder to underwrite.
growth
weight-management product launch
MindBody GLP-1 System
launched oct 2024
The launch timing is clear. The read-through is not. The next quarter saw a 28% revenue decline, which means the new system did not offset weakness elsewhere fast enough.
new bet
Key numbers
8.4x
trailing p/e
That is the price of a company the market does not trust, even after 14.2% annual revenue growth.
76.7%
gross margin
Gross margin means money left after product costs, so this tells you the products themselves are very profitable.
22.1%
return on capital
Return on capital means profit earned on the money used in the business, and 22.1% says management is not wasting it.
3.5%
dividend yield
You are getting paid to wait, which matters when a tiny stock has uneven quarterly results.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 10 / 100
- long-term debt $9M (12% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for LFVN right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Quarterly revenue near ~$57M (order of ¼ of ~$229M FY); EPS near $0.19 in one feed print—verify against the 10-Q.
Prior $96M / 97% vs. prior year lines were inconsistent with the ~$229M year (and with guidance cuts to ~$185M–$200M called out in risks). 76.7% gross margin is the cleaner through-line.
~$57M
Q revenue (approx.)
$0.19
eps
76.7%
gross margin
the number that mattered
76.7% gross margin matters most—use it as the quality check while revenue period labels get cleaned up.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is a failed stabilization after the fy2026 guidance reset. this is not a vague "execution" issue. the company already told you revenue is coming in at $185M–$200M instead of above $225M.
med
guidance reset becomes a trend, not a one-off
Q2 FY2026 revenue fell 28% from a year ago, and management cut full-year guidance to $185M–$200M. If the next quarters do not stabilize inside that range, the "cheap stock" argument gets weaker fast.
The gap versus expectations above $225M puts roughly $25M–$40M of annual revenue at issue.
med
too much of the story still rides on a few products
This snapshot points repeatedly to Petandim® and newer launches like MindBody GLP-1 System, but does not give clean product-level sales. That's a problem. If your stock thesis depends on one or two franchises, you want cleaner disclosure than this.
When product concentration is high and disclosure is thin, surprises hit harder than the 35/100 predictability score already suggests.
med
the dividend starts competing with the turnaround
A 3.5% dividend yield sounds shareholder-friendly. It also costs about $2.3M per quarter. For a $66M company with falling sales, that is real cash that could otherwise support the business.
If pressure persists, management may have to choose between defending the payout and defending flexibility.
A business guiding to $185M–$200M in revenue while paying out about $2.3M each quarter leaves itself less room for error. The combined risk is simple: weaker sales, unclear product mix, and a dividend that becomes more expensive every time the story shrinks.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
fy2026 revenue range
$185M–$200M is the line that matters now. If management lands near the low end or below it, the reset is not finished.
calendar
next earnings update
You want one thing from the next print: proof that the 28% drop was the low point, not the new trend.
risk
dividend pressure
The payout costs about $2.3M per quarter. If revenue keeps shrinking, income investors stop seeing yield and start seeing strain.
trend
americas versus the rest
Americas is roughly 61% of revenue and recently down about 30%, while Asia Pacific / Other is roughly flat. Same company. Very different trajectories.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak: nobody has a clean consensus because the operating picture just changed.
risk profile
volatile
a 10/100 price stability score tells you this can move hard on small-cap sentiment and company-specific disappointments.
chart momentum
headline-driven
the chart matters less than the next revenue print. Welcome to small-cap turnaround investing.
earnings predictability
35/100
that's a low score. In plain English: quarterly numbers can surprise you, and not in a fun way.
source: institutional data
Institutional activity
institutional ownership data for LFVN is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$6
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive